Invokana vs. Glimepiride
See how Invokana and Glimepiride compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Invokana is an SGLT2 inhibitor with added FDA approvals for heart and kidney protection, while glimepiride is a sulfonylurea used only for blood sugar control.
Glimepiride carries a real risk of hypoglycemia and costs far less than Invokana, while Invokana carries risks of genital infections and lower limb amputation.
Both drugs are taken by mouth once daily, but only Invokana has FDA-backed evidence of reducing cardiovascular events and slowing kidney disease.
Invokana vs. Glimepiride Drug Summary
Invokana
Invokana (canagliflozin) is an SGLT2 inhibitor for adults and children age 10 and older with type 2 diabetes. It is taken as a single tablet by mouth once daily, starting at 100 mg and increasing to 300 mg if more blood sugar control is needed. Beyond glycemic control, it is also approved to reduce cardiovascular and kidney complications in certain patients.
Glimepiride
Glimepiride is a sulfonylurea tablet used as an add-on to diet and exercise for type 2 diabetes. It is taken once daily by mouth, usually starting at 1 mg and increasing gradually to a maximum of 8 mg if more blood sugar control is needed. It has been used since 1995 and lowers blood sugar by prompting the pancreas to release more insulin.
Invokana vs. Glimepiride Side Effects
Invokana
Glimepiride
Invokana vs. Glimepiride Dosage
Invokana
Glimepiride
| STAGE | DOSE | WHEN |
| Starting dose | 100 mg once daily | At the start |
| Maximum dose | 100 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
| STAGE | DOSE | WHEN |
| Starting dose | 1 mg once daily | At the start |
| Maximum dose | 8 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
Invokana
| STAGE | DOSE | WHEN |
| Starting dose | 100 mg once daily | At the start |
| Maximum dose | 100 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
Glimepiride
| STAGE | DOSE | WHEN |
| Starting dose | 1 mg once daily | At the start |
| Maximum dose | 8 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
Invokana vs. Glimepiride Indications
Invokana
Invokana is an SGLT2 inhibitor approved to improve blood sugar control in adults and children age 10 and older with type 2 diabetes. It also carries specific approvals to lower cardiovascular risk in adults with heart disease and to slow kidney disease progression in those with diabetic nephropathy. It is not approved for type 1 diabetes or diabetic ketoacidosis.
Adjunct to diet and exercise for blood sugar control in type 2 diabetes
Reduces risk of heart attack, stroke, and cardiovascular death in adults with known heart disease
Reduces risk of kidney failure, heart failure hospitalization, and cardiovascular death in diabetic kidney disease
Approved for children age 10 and older with type 2 diabetes
Not approved for type 1 diabetes or diabetic ketoacidosis
Glimepiride
Glimepiride is a sulfonylurea approved as an add-on to diet and exercise to help control blood sugar in adults with type 2 diabetes. Unlike newer diabetes medicines such as Invokana, its FDA label does not claim any proven heart or kidney benefit. It is not approved for type 1 diabetes or diabetic ketoacidosis.
Adjunct to diet and exercise for blood sugar control in type 2 diabetes
No FDA-recognized cardiovascular or kidney protection benefit
One of the oldest oral diabetes medicines, FDA-approved since 1995
Must be stopped at least two weeks before expected delivery
Not approved for type 1 diabetes or diabetic ketoacidosis
Invokana vs. Glimepiride Pros and Cons
Invokana
Invokana carries FDA approvals beyond blood sugar control, including reducing cardiovascular and kidney complications, which most oral diabetes pills cannot claim. It carries a warning for increased lower limb amputation risk, and genital yeast infections are common. Most insurance plans cover it, though the list price is far higher than older generic options.
Pros
Proven to reduce heart attack, stroke, and cardiovascular death in patients with heart disease
Only oral diabetes pill FDA-approved to slow diabetic kidney disease progression
Can support modest weight loss alongside blood sugar control
Very low risk of hypoglycemia when used alone
Cons
Higher risk of genital yeast infections and urinary tract infections
Carries an FDA warning for increased lower limb amputation risk
Not recommended once kidney function drops below a certain level
Costs roughly $550 to $830 per month without insurance
Glimepiride
Glimepiride is one of the least expensive type 2 diabetes medicines available, with decades of clinical use behind it. It lowers blood sugar effectively, but carries a real risk of low blood sugar episodes and lacks FDA-recognized heart or kidney benefits. Older sulfonylureas like this one also carry an FDA warning about a possible increase in cardiovascular death.
Pros
Costs roughly $10 to $20 per month, among the cheapest diabetes drugs available
Long track record of use since its FDA approval in 1995
Simple once-daily oral dosing with no injections involved
Works quickly to bring blood sugar down
Cons
Meaningful risk of hypoglycemia, especially with missed or delayed meals
FDA warning about a possible increase in cardiovascular mortality with sulfonylureas
No proven cardiovascular or kidney protective benefit
Risk of hemolytic anemia in patients with G6PD deficiency
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.